iPSC Generation Services
Let the iPSC experts generate high-quality, induced pluripotent stem cells (iPSC) and derived physiologically relevant cell line models from your healthy/disease human or non-human samples. If you do not have a starting sample, Applied StemCell (ASC) offers customizable sample collection services. With our optimized reprogramming protocols and comprehensive characterization services, we deliver iPSCs ideal for your basic research, drug discovery, drug screening, and preclinical cell regeneration projects:
- Highly optimized protocols with high reprogramming efficiency (>95% success rate)
- From healthy/diseased human or non-human samples
- iPSC generation from human PBMCs, fibroblast, HSC, MSCs, CD34+ cord blood, urine, and more; non-human PBMC and fibroblast
- Integration-free (episomal/mRNA/viral-based) or retroviral reprogramming
- Feeder-free protocols; optional feeder-dependent protocols available
- iPSCs characterized for morphology and pluripotency markers. Additional characterization such as G-banding, RT-PCR, STR profiling, directed differentiation is also available.
Not only can ASC further characterize your iPSCs, but our experts can also genetically engineer your iPSCs using CRISPR/Cas9 or TARGATT™ and differentiate the iPSCs to the cell type of your choice, including NK cells, T cells, astrocytes, cardiomyocytes, and more.
GMP Grade iPSC Services & Products
Allogenic & Immunocompatible iPSC Generation
iPSC Generation From Non-Human Species
For iPSC generation from patient fibroblasts, customers will need to provide 1 x 10^6 cells.
For iPSC generation from PBMCs, we will need 2 vials of 2-3 x 10^6 cells.
Yes, we can receive skin biopsy. The skin biopsy can be stored immediately after the collection and shipped overnight in PBS or complete medium (DMEM/10% FBS) at 4°C.
Turnaround time: 2-3 months
iPSCs characterized for morphology and pluripotency markers (OCT4, SOX2, SSEA4, TRA-1-60, TRA-1-81). Additional characterization such as G-banding, RT-PCR, STR profiling, directed differentiation is also available.
|Catalog ID#||Product Name||Format||Size||Price|
- Jang, Y., Choi, J., Park, N., Kang, J., Kim, M., Kim, Y., & Ju, J. H. (2019). Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering. Experimental & Molecular Medicine, 51(1), 3.
- Ilic, D. (2019). Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions in October 2018. Regenerative medicine, 14(2), 85-92.
- Allende, M. L., Cook, E. K., Larman, B. C., Nugent, A., Brady, J. M., Golebiowski, D., ... & Proia, R. L. (2018). Cerebral organoids derived from Sandhoff disease induced pluripotent stem cells exhibit impaired neurodifferentiation. Journal of Lipid Research, jlr-M081323.
- Field, A. R., Jacobs, F. M., Fiddes, I. T., Phillips, A. P., Reyes-Ortiz, A. M., LaMontagne, E., ... & Hauessler, M. (2019). Structurally Conserved Primate LncRNAs Are Transiently Expressed during Human Cortical Differentiation and Influence Cell-Type-Specific Genes. Stem cell reports.